NIZATIDINE

Post-LOE

nizatidine

ANI Pharmaceuticals

ANDAORALCAPSULE

Approved

Jul 2002

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

3/8 — Basic

NIZATIDINE (nizatidine) by ANI Pharmaceuticals is histamine h2 receptor antagonists [moa]. First approved in 2002.

Drug data last refreshed 19h ago

Mechanism of Action

Histamine H2 Receptor Antagonists

Pharmacologic Class:

Histamine-2 Receptor Antagonist

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (2)

NCT01161927Phase 1Completed

Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Non- Fasting Conditions

Started Jul 2004

26 enrolled

Healthy

NCT01161940Phase 1Completed

Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions

Started Jul 2004

26 enrolled

Healthy

Company

Worked on NIZATIDINE at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.